Anne-Liv Schulz
Overview
Explore the profile of Anne-Liv Schulz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rubio-Nazabal E, Majoie M, Schulz A, Brock F, Leunikava I, Bourikas D, et al.
Neurol Ther
. 2025 Feb;
14(2):609-625.
PMID: 39976892
Introduction: This analysis aimed to evaluate patient-related outcomes for health-related quality of life (HRQoL) and cognitive performance in patients (≥ 16 years) with focal-onset seizures (FOS), with/without focal to bilateral...
2.
Steinhoff B, Christensen J, Doherty C, Majoie M, Schulz A, Brock F, et al.
Neurol Ther
. 2025 Feb;
14(2):627-642.
PMID: 39976891
Introduction: Efficacy/tolerability of adjunctive brivaracetam (BRV) for focal-onset seizures (FOS) in patients aged ≥ 16 years was established in randomized controlled trials. This study aimed to evaluate the effectiveness of...
3.
Bast T, Schulz A, Floricel F, Morita D, Cleveland J, Elshoff J
Epilepsia Open
. 2022 Jul;
7(4):588-597.
PMID: 35844134
Objective: Despite introduction of several antiseizure medications over the past two decades, treatment options for childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE) remain limited. We report the innovative...
4.
Toledo M, Brandt C, Quarato P, Schulz A, Cleveland J, Wagener G, et al.
Epilepsy Behav
. 2021 Mar;
118:107897.
PMID: 33780735
Objectives: The primary objective of this long-term follow-up (LTFU) trial was to evaluate the long-term safety and tolerability of brivaracetam (BRV). The secondary objective was to evaluate the maintenance of...
5.
Ben-Menachem E, Baulac M, Bong Hong S, Cleveland J, Reichel C, Schulz A, et al.
Epilepsy Res
. 2021 Jan;
170:106526.
PMID: 33461041
This long-term open-label extension (OLE) trial was conducted to evaluate the long-term safety and tolerability of brivaracetam (BRV) at individualized doses in patients with epilepsy and focal (partial-onset) or generalized...
6.
Lerche H, Knake S, Rosenow F, Schulze-Bonhage A, Hellot S, Leunikava I, et al.
Epilepsia Open
. 2020 Sep;
5(3):451-460.
PMID: 32913953
Objective: To evaluate the success of initiation of adjunctive brivaracetam in patients who required a change in antiepileptic drug (AED) regimen and substituted at least one AED with brivaracetam. Methods:...
7.
Arnold S, Laloyaux C, Schulz A, Elmoufti S, Yates S, Fakhoury T
Epilepsy Res
. 2020 Jul;
166:106404.
PMID: 32731118
Background: This long-term follow-up (LTFU) trial was conducted to evaluate the long-term safety and tolerability of brivaracetam (BRV) at individualized doses (maximum of 200 mg/day) in patients with focal seizures....
8.
OBrien T, Borghs S, He Q, Schulz A, Yates S, Biton V
Epilepsia
. 2020 Mar;
61(4):636-646.
PMID: 32221987
Objective: To evaluate long-term safety/tolerability of brivaracetam at individualized doses ≤200 mg/d (primary) and maintenance of efficacy over time (secondary) in adults with focal seizures or primary generalized seizures (PGS)...